Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome

López‐Pedrera, Chary; Ruiz-Limón, P.; Aguirre, María Ángeles; Barbarroja, Nuria; Pérez-Sánchez, C.; Buendía, Paula; Rodriguez-García, Ines-Carmen; Rodríguez‐Ariza, Antonio; Collantes-Estévez, Eduardo; Velasco, Francisco; Khasmahta, Munther; Cuadrado, María J.

doi:10.1136/ard.2010.135525

Cited by 84 publications

(47 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Likewise, in systemic lupus erythematosus (SLE), MetS was found to be associated with other traditional risk factors for coronary heart disease, mainly obesity and LDL cholesterol Ͼ100 mg/dl (34), reinforcing the idea of risk factor clustering in autoimmune diseases. Of note, one-fourth of our patients were taking statins, a drug with known antiinflammatory, anticoagulant, and immunoregulatory effects (35). Its possible contribution to thrombosis prevention in our APS patients deserves further studies, since statins have multiple profound effects in monocyte activity by a significant inhibition on the protein expression of tissue factor (35).…”

Section: Discussionmentioning

confidence: 91%

“…Of note, one-fourth of our patients were taking statins, a drug with known antiinflammatory, anticoagulant, and immunoregulatory effects (35). Its possible contribution to thrombosis prevention in our APS patients deserves further studies, since statins have multiple profound effects in monocyte activity by a significant inhibition on the protein expression of tissue factor (35).…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome

Rodrigues

Bonfá

Caleiro

et al. 2012

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. Metabolic syndrome (MetS) is highly prevalent in rheumatic diseases and is recognized as a new independent cardiovascular risk factor. This study was undertaken to determine the clinical significance of MetS in patients with primary antiphospholipid syndrome (APS). Methods. Seventy-one primary APS patients and 73 age-and sex-matched healthy controls were included. Serum samples were tested for lipid profile, Lp(a), glucose, insulin, thyroid-stimulating hormone, free T4, erythrocyte sedimentation rate, C-reactive protein level, and uric acid. MetS was defined by the International Diabetes Federation criteria, and insulin resistance was established using the homeostasis model assessment index. Results. The prevalence of MetS was 33.8%, and further comparison between primary APS patients with and withoutMetS revealed that the former had a higher frequency of arterial events (79.2% versus 42.6%; P ‫؍‬ 0.003), angina (29.2% versus 2.1%; P ‫؍‬ 0.002), and positive lupus anticoagulant antibody (95.8% versus 76.6%; P ‫؍‬ 0.049). In addition, primary APS patients with MetS, as expected, had a higher prevalence of cardiovascular risk factors. On multivariate analysis, only MetS was independently associated with arterial events in primary APS. Conclusion. Coexistence of primary APS and MetS seems to identify a subgroup of patients with higher risk of arterial events, suggesting that MetS may aggravate existing endothelial abnormalities of primary APS.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 91%

Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome

Rodrigues

Bonfá

Caleiro

et al. 2012

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…Very recently, proteomic study of monocytes and endothelial cells in patients with APS who received fluvastatin for one month, confirmed a significant reduction in the expression of TF, PAR-1, 2 and VEGF, which is associated with inhibition of the p38MAPK and NF-kB pathway [ 66 ]. Furthermore, Shoenfeld et al, based on the immunoregulatory and possibly antithrombotic effect of vitamin D, studied the serum levels of vitamin in patients with APS and its in vitro effects in HUVEC.…”

Section: Clinical and Laboratory Characteristicsmentioning

confidence: 94%

Pathogenic Mechanisms of Thrombosis in Antiphospholipid Syndrome (APS)

Sikara¹,

Grika²,

Vlachoyiannopoulos³

2011

Thrombophilia

View full text Add to dashboard Cite

“…Given their positive effects on the immune system, on the vascular endothelium and on PONa (reviewed in [73]), statins may be suitable candidates within the context of a clinical trial. Indeed, an in vitro study showed that pravastatin was effecting at reverting the pro-adhesive and pro-thrombotic phenotype induced by aPL on endothelial cells, and a one month interventional trial with fluvastatin restored monocyte function in patients with APS [74,75]. Probucol ameliorated coagulation activation and lipid peroxidation in PAPS [76].…”

Section: Management Of Paps Related Atherosclerosismentioning

confidence: 99%

Atherosclerosis in Primary Antiphospholipid Syndrome: Summary of Clinical and Pathogenic Evidence

Prj

Matsuura³

et al. 2014

J Clin Exp Cardiolog

View full text Add to dashboard Cite

The Antiphospholipid Syndrome (APS) was described in the early '80s as a combination of thrombosis, thrombocytopenia and recurrent miscarriages associated with persistent high titers of Antiphospholipid Antibodies (aPL). In subsequent years, it became apparent that aPL were also associated with premature atherosclerosis in Systemic Lupus Erythematosus (SLE) and more recently in primary APS (PAPS). The studies exploring atherosclerosis in PAPS were heterogeneous in conception and size, but overall, provided enough evidence that Intima Media Thickness (IMT) of carotid arteries and endothelial function are abnormal in PAPS. In keeping with the general view that atherosclerosis is a low grade inflammatory and "auto"immune disorder characterised by oxidative and nitrative stress, several studies have confirmed similar findings in PAPS, though a specific relation with the severity of atherosclerosis is lacking. Given its development at an earlier age than average, atherosclerosis should be taken into account in the overall management of PAPS patients as it may significantly add to the vascular risk.

show abstract

Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome

Abstract: The data from this study support the belief that fluvastatin has multiple profound effects in monocyte activity, which might contribute to thrombosis prevention in APS patients.

Cited by 84 publications

References 35 publications

Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome

Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome

Pathogenic Mechanisms of Thrombosis in Antiphospholipid Syndrome (APS)

Atherosclerosis in Primary Antiphospholipid Syndrome: Summary of Clinical and Pathogenic Evidence

Contact Info

Product

Resources

About